e-learning
resources
Munich 2014
Tuesday, 09.09.2014
ILDs: pathogenesis and clinical features
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pirfenidone and BIBF1120 regulate properties of myofibroblasts
S. Lehtonen, H. Karvonen, E. Lappi-Blanco, R. Sormunen, U. Zagai, M. Sköld, R. Kaarteenaho (Oulu, Finland; Stockhom, Sweden)
Source:
International Congress 2014 – ILDs: pathogenesis and clinical features
Session:
ILDs: pathogenesis and clinical features
Session type:
Poster Discussion
Number:
3502
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Lehtonen, H. Karvonen, E. Lappi-Blanco, R. Sormunen, U. Zagai, M. Sköld, R. Kaarteenaho (Oulu, Finland; Stockhom, Sweden). Pirfenidone and BIBF1120 regulate properties of myofibroblasts. Eur Respir J 2014; 44: Suppl. 58, 3502
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Sensitivity analyses from the INPULSIS™ trials of nintedanib
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Parenchymal cell populations involved in the development of fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts
Source: International Congress 2014 – ILDs 2
Year: 2014
Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept